OncoMatch/Clinical Trials/NCT06255223
A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy
Is NCT06255223 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Anti-PD-1 monoclonal antibody for renal cell carcinoma.
Treatment: Anti-PD-1 monoclonal antibody — The objective of this single-center clinical study was to evaluate the disease control rate(DCR) and safety of multimodal radiotherapy in the treatment of patients with renal cell carcinoma (RCC) progressed after prior immunotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Renal Cell Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: immune checkpoint inhibitor — at least one regimen containing immune checkpoint inhibitors, including combined VEGFR-TKI drugs
Disease progression or intolerance following prior treatment with 1-2 systemic therapies (at least one regimen containing immune checkpoint inhibitors, including combined VEGFR-TKI drugs)
Cannot have received: radiation therapy
Previous history of radiation therapy at any site or in any mode.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify